Favorable Response to Pemetrexed as a Salvage Agent for Patients with Advanced Lung Cancer Who Have Failed Conventional Platinum-Based Chemotherapy and EGFR Tyrosine Kinase Inhibitors

貢獻的翻譯標題: Pemetrexed 對含鉑化療及EGFR 酪氨酸激酶抑制劑無效的非小細胞型肺癌仍有良好的療效

研究成果: 雜誌貢獻文章

摘要

背景:對於局部晚期或轉移性之非鳞狀細胞型非小細胞型肺癌,Pemetrexed 目前可與
鉑類藥物併用作為第一線用藥或於含鉑化學治療後的第二線用藥,但有關此藥用於第
三線治療的療效及此藥於第三線使用時,EGFR 及 K-ras 基因突變對其反應的影響的
相關文獻很少。
方法:我們回溯分析此藥用於已對第一線含鉑化療及對 erlotinib 或 gefitinib 無效後的
病人時,病人性別、performance status、給藥週期數、EGFR 及 K-ras 基因突變型態、
化療反應、不良反應,及有效期及整體存活對此藥療效之影響。
結果:平均病人使用 6.17 週期,十一個病人中有六個有部份反應,三個穩定疾病,
兩個無效。平均有效期及整體存活為 108 天及 346 天。EGFR 基因突變的有無不影響
療效,此藥用於第三線的耐受良好,無病人須作劑量調整。
結論:pemetrexed 對 performance status 良好的病人在其對第一線含鉑化療及 EGFR 酪
氨酸激酶抑制劑無效時仍為良好選擇。
原文英語
頁(從 - 到)281-286
頁數6
期刊中華民國癌症醫學會雜誌
25
發行號4
出版狀態已發佈 - 八月 2009

指紋

Pemetrexed
Proxy
Platinum
Protein-Tyrosine Kinases
Lung Neoplasms
Drug Therapy
Mutation
Survival
Non-Small Cell Lung Carcinoma
Disease Progression
Therapeutics

Keywords

  • 非小細胞型肺癌
  • EGFR 酪氨酸激酶抑制劑
  • pemetrexed
  • Non-small cell lung cancer
  • EGFR tyrosine kinase inhibitors

引用此文

@article{05cd9b9d75f64b6fb7a7b8299d055f41,
title = "Favorable Response to Pemetrexed as a Salvage Agent for Patients with Advanced Lung Cancer Who Have Failed Conventional Platinum-Based Chemotherapy and EGFR Tyrosine Kinase Inhibitors",
abstract = "Background: For locally advanced or metastatic non-squamous non-small cell lung cancer(NSCLC), pemetrexed is currently recommended as first-line treatment in combination withplatinum agents or second-line chemotherapy after the disease has become refractory to platinum-baseddoublet regimens, but few reports have addressed its role as salvage chemotherapyafter failure of multiple therapies and the relationship between response rate and EGFR andK-ras mutations.Methods: We retrospectively evaluated the efficacy of pemetrexed in 11 patients with advancedNSCLC, who had failed at least platinum-based doublet combinations and erlotinib or gefitinib.The gender, performance status, number of cycles given, EGFR and K-ras mutation status, bestresponse, adverse reactions, time to progression (TTP) and overall survival (OS) were used toassess the effects.Results: A median of 6.17 cycles of infusion was given. Six out of 11 patients experienced partialresponse, three stable disease and two disease progression. The TTP and OS of salvage pemetrexedtherapy were 108 and 346 days, respectively. The EGFR mutation status did not affectits efficacy. It was well-tolerated and required no dose modification.Conclusions: Pemetrexed is a good option for patients with good performance status who havefailed platinum- and taxane-containing regimens and EGFR tyrosine kinase inhibitors.",
keywords = "非小細胞型肺癌, EGFR 酪氨酸激酶抑制劑, pemetrexed, Non-small cell lung cancer, EGFR tyrosine kinase inhibitors, 非小細胞型肺癌, EGFR 酪氨酸激酶抑制劑, pemetrexed, Non-small cell lung cancer, EGFR tyrosine kinase inhibitors",
author = "Hung, {Wen Yueh} and Chun-Nin Lee and Kuan-Jen Bai and Ming-Chih Yu and Chang, {Jer Hwa} and Hsu, {Han Lin} and Hsingjin-Eugene Liu",
year = "2009",
month = "8",
language = "English",
volume = "25",
pages = "281--286",
journal = "中華民國癌症醫學會雜誌",
issn = "1015-6267",
publisher = "中華民國癌症醫學會",
number = "4",

}

TY - JOUR

T1 - Favorable Response to Pemetrexed as a Salvage Agent for Patients with Advanced Lung Cancer Who Have Failed Conventional Platinum-Based Chemotherapy and EGFR Tyrosine Kinase Inhibitors

AU - Hung, Wen Yueh

AU - Lee, Chun-Nin

AU - Bai, Kuan-Jen

AU - Yu, Ming-Chih

AU - Chang, Jer Hwa

AU - Hsu, Han Lin

AU - Liu, Hsingjin-Eugene

PY - 2009/8

Y1 - 2009/8

N2 - Background: For locally advanced or metastatic non-squamous non-small cell lung cancer(NSCLC), pemetrexed is currently recommended as first-line treatment in combination withplatinum agents or second-line chemotherapy after the disease has become refractory to platinum-baseddoublet regimens, but few reports have addressed its role as salvage chemotherapyafter failure of multiple therapies and the relationship between response rate and EGFR andK-ras mutations.Methods: We retrospectively evaluated the efficacy of pemetrexed in 11 patients with advancedNSCLC, who had failed at least platinum-based doublet combinations and erlotinib or gefitinib.The gender, performance status, number of cycles given, EGFR and K-ras mutation status, bestresponse, adverse reactions, time to progression (TTP) and overall survival (OS) were used toassess the effects.Results: A median of 6.17 cycles of infusion was given. Six out of 11 patients experienced partialresponse, three stable disease and two disease progression. The TTP and OS of salvage pemetrexedtherapy were 108 and 346 days, respectively. The EGFR mutation status did not affectits efficacy. It was well-tolerated and required no dose modification.Conclusions: Pemetrexed is a good option for patients with good performance status who havefailed platinum- and taxane-containing regimens and EGFR tyrosine kinase inhibitors.

AB - Background: For locally advanced or metastatic non-squamous non-small cell lung cancer(NSCLC), pemetrexed is currently recommended as first-line treatment in combination withplatinum agents or second-line chemotherapy after the disease has become refractory to platinum-baseddoublet regimens, but few reports have addressed its role as salvage chemotherapyafter failure of multiple therapies and the relationship between response rate and EGFR andK-ras mutations.Methods: We retrospectively evaluated the efficacy of pemetrexed in 11 patients with advancedNSCLC, who had failed at least platinum-based doublet combinations and erlotinib or gefitinib.The gender, performance status, number of cycles given, EGFR and K-ras mutation status, bestresponse, adverse reactions, time to progression (TTP) and overall survival (OS) were used toassess the effects.Results: A median of 6.17 cycles of infusion was given. Six out of 11 patients experienced partialresponse, three stable disease and two disease progression. The TTP and OS of salvage pemetrexedtherapy were 108 and 346 days, respectively. The EGFR mutation status did not affectits efficacy. It was well-tolerated and required no dose modification.Conclusions: Pemetrexed is a good option for patients with good performance status who havefailed platinum- and taxane-containing regimens and EGFR tyrosine kinase inhibitors.

KW - 非小細胞型肺癌

KW - EGFR 酪氨酸激酶抑制劑

KW - pemetrexed

KW - Non-small cell lung cancer

KW - EGFR tyrosine kinase inhibitors

KW - 非小細胞型肺癌

KW - EGFR 酪氨酸激酶抑制劑

KW - pemetrexed

KW - Non-small cell lung cancer

KW - EGFR tyrosine kinase inhibitors

UR - http://www.cos.org.tw/Jour/Letter.asp?sub=2&Continue=Y

M3 - Article

VL - 25

SP - 281

EP - 286

JO - 中華民國癌症醫學會雜誌

JF - 中華民國癌症醫學會雜誌

SN - 1015-6267

IS - 4

ER -